Summit, Akeso report another Phase 3 win for PD-1xVEGF approach in lung cancer
Summit Therapeutics and Akeso said their PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a Phase 3 study in lung cancer patients in China. The readout marks the third late-stage win for ivonescimab ...
Summit Therapeutics and Akeso said their PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a Phase 3 study in lung cancer patients in China.
The readout marks the third late-stage win for ivonescimab ...
